Find Clinical Trials
Effect of 3 doses (20, 40 and 60 mg) of a sublingual formulation of piribedil (S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson’s disease patients after a 14-day treatment-period (one administration t.i.d.). A randomised, double-blind study consisting of 3 cross-over: 40 mg versus placebo, 20 mg versus 60 mg and 40 mg versus 20 mg. – PARKOPI
Servier Protocol Code:
SC2-90049-003
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2005-000314-12
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Parkinson's disease
- PIRIBEDIL
- S090049
Other study id numbers
Other identification numbers the study may be known by.
- SC2-90049-003